Notice of R&D presentation
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your TCF notes
Alderley Park, 22 May 2024 - TheraCryf plc (AIM: TCF), formerly Evgen Pharma plc, the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that it will hold a Research and Development update event at 09:30am on 13 June 2024.
The event will be held at the offices of Instinctif Partners located at 65 Gresham Street, London EC2V 7NQ is open to sell-side analysts and all existing and potential shareholders. Investors and analysts will be able attend the event in person or virtually via a link which will be distributed to registered attendees.
The morning will comprise an update on TheraCryf, including the Chronos acquisition and update on the integration; discussion about the clinical programme in glioblastoma and the preclinical programmes in neuropsychiatry. The session will also include a discussion about market potential and the ongoing strategy.
Speakers will include members of the TheraCryf (and former Chronos) management and scientific team, and external speakers including Dr Marjolein Geurts, neuro-oncologist and Dr Wouter Vanbilloen MD, neurology resident from Erasmus University Medical Center.
To register your attendance, please email theracryf@instinctif.com or register via the Investor Meet Company platform HERE.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.